62802-42-0

Basic information

• Product Name: 2-Chloro-5-fluoropyrimidine
• Synonyms: 2-CHLORO-5-FLUOROPYRIMIDINE;Pyrimidine, 2-chloro-5-fluoro- (9CI);Pyrimidine,2-chloro-5-fluoro-;2-Chloro-5-fluoropyrimidine ,98%;2-Chloro-5-fluoropyr;2-Chloro-5-fluoropyriMidi...;2-Chloro-5-fluoro-1,3-diazine
• CAS NO: 62802-42-0
• Molecular Formula: C₄H₂ClFN₂
• Molecular Weight: 132.52
• Product Categories: PYRIMIDINE;Pyrimidine series;pharmacetical;Pyrimidines;Bases & Related Reagents;Nucleotides;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;PyrimidinesHeterocyclic Building Blocks;Variety of halogenated heterocyclic series;Fluorine series
• Mol File: 62802-42-0.mol

Chemical Properties

• Boiling Point: 149.0-162.0°C
• Flash Point: 150 °F
• Appearance: Clear colorless to yellow/Liquid
• Density: 1.073 g/mL at 25 °C(lit.)
• Vapor Pressure: 9.41E-07mmHg at 25°C
• Refractive Index: n20/D 1.503(lit.)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.54±0.22(Predicted)
• CAS DataBase Reference: 2-Chloro-5-fluoropyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-fluoropyrimidine(62802-42-0)
• EPA Substance Registry System: 2-Chloro-5-fluoropyrimidine(62802-42-0)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-34-41-37/38
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 2735 8/PG 2
• WGK Germany: 3
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 62802-42-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-fluoropyrimidine is used as a key intermediate for the preparation of 2,4-disubstituted-5-fluoropyrimidine, which is a biologically active molecule found in anticancer agents like 5-fluorouracil. It plays a significant role in the development of novel cancer treatments.
2-Chloro-5-fluoropyrimidine is also used as a starting material for the preparation of:
1. 5-fluoro-2-amino pyrimidines by reacting with various amines in the presence of K2CO3, via C-N bond forming reaction. These compounds have potential applications in the development of new pharmaceuticals.
2. 2-chloro-5-(5-fluoropyrimidin-2-yl)benzoic acid, an intermediate used in the synthesis of benzamide scaffolds. These benzamides are potent antagonists against P2X7 receptors, which are involved in various physiological processes and could be targeted for therapeutic intervention.
3. 5-fluoro-2-cyano pyrimidine, a key intermediate used for the synthesis of 5-chloro-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine. 2-Chloro-5-fluoropyrimidine acts as a potent inhibitor of the JAK2 kinase, which is a target for various diseases, including cancer and inflammatory conditions.

Preparation

Synthesis of 2-chloro-5-fluoropyrimidine: add 2,4-Dichloro-5-fluoropyrimidine and reducing metal powder to the solvent, stir to raise the temperature to the reaction temperature, slowly add acid dropwise, and keep the temperature until the reaction is completed Finish. Filtration, phase separation or direct evaporation of the solvent, and distillation under reduced pressure to remove the solvent to obtain 2-chloro-5-fluoropyrimidine.

InChI:InChI=1/C6H3ClFNO2/c7-5-4(8)3(6(10)11)1-2-9-5/h1-2H,(H,10,11)

Upstream product

• 2927-71-1 2,4-dichloro-5-fluoropyrimidine 
• 6693-08-9 2,4,6-trichloro-5-fluoropyrimidine 

Downstream Products

• 87789-49-9 5-fluoro-2-(piperazin-1-yl)-pyrimidine 
• 1001398-05-5 4-{[1-(5-fluoro-2-pyrimidinyl)-4-piperidinyl]oxy}-1-[4-(methylsulfonyl)phenyl]-2,3-dihydro-1H-indole 
• 874646-11-4 5-fluoro-2-[(3R)-3-methylpiperazin-1-yl]pyrimidine 
• 545424-37-1 4-(5-fluoro-pyrimidin-2-yl)-benzaldehyde 
• 38275-55-7 5- fluoropyrimidine-2-carbonitrile 
• 455265-89-1 4-[(5-fluoro-pyrimidin-2-ylamino)-methyl]-piperidine-1-carboxylic acid benzyl ester 
• 1190280-60-4 C₁₄H₁₁FN₄ 
• 1190280-65-9 C₁₅H₁₀F₄N₄ 
• 1032825-49-2 [1-(5-fluoro-2-pyrimidinyl)-4-piperidinyl]methanol 
• 1205537-14-9 C₂₂H₁₈ClFN₈ 
• 1227807-75-1 C₁₁H₆ClFN₂O₂ 
• 1245899-93-7 C₃₀H₃₄FN₃O₃S 
• 1258532-42-1 C₁₇H₂₁FN₄O₂ 
• 1201633-30-8 C₁₇H₁₉FN₄ 

Relevant articles and documents

IMIDAZOTRIAZINONE COMPOUNDS

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis

Two series of N-hydroxyformamide inhibitors of ADAM-TS4 were identified from screening compounds previously synthesised as inhibitors of matrix metalloproteinase-13 (collagenase-3). Understanding of the binding mode of this class of compound using ADAM-TS1 as a structural surrogate has led to the discovery of potent and very selective inhibitors with favourable DMPK properties. Synthesis, structure-activity relationships, and strategies to improve selectivity and lower in vivo metabolic clearance are described.

SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME

Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.

Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders

Aryl sulfonamide and sulfonyl compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists

Compounds represented by Formula (I): 1or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

Synthesis and anxiolytic activity of N-substituted cyclic imides (1R*,2S*3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3-b icyclo[2.2.1]heptanedicarboxime (Tandospirone) and related compounds

A series of cyclic imides bearing a ω-(4-aryl and 4-heteroaryl-1-piperazinyl)alkyl moieties was synthesized and tested in vivo for anxiolytic activity. The in vitro binding affinities of these compounds were also examined for 5-HT(1A) receptor sites. Structure-activity relationships within these series are discussed. One of these compounds, (1R*,2S*,3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3- bicyclo[2.2.1]heptanedicarboximide (1: tandospirone), was found to be equipotent with buspirone in its anxiolytic activity and more anxio-selective than buspirone and diazepam. Tandospirone (1) is currently undergoing clinical evaluation as a selective anxiolytic agent.

A NEW ROUTE TO THE SYNTHESIS OF 5-FLUOROURACIL

Starting from tetrafluoropyrimidine (1), selective fluorine/chlorine exchange reactions and selective hydrogenolysis of the chlorine substituents are described.Combination of these methods, together with a subsequent hydrolysis reaction, provides a new route to the synthesis of 5-fluorouracil via 4,6-dichloro-2,5-difluoropyrimidine and 4-chloro-2,5-difluoropyrimidine.

Chemoselectivity and Regoselectivity in Reactions of Pyrimidines

Selective nucleophilic substitution and hydrogenolysis reactions in pyrimidines are discussed.Stepwise oxidation reactions of pyrimidine sulfides and HPLC studies of these are reported.